| Literature DB >> 33143749 |
Yasser M Kazzaz1,2,3, Haneen AlTurki4,5, Lama Aleisa4,5, Bashaer Alahmadi4,5, Nora Alfattoh4,5, Nadia Alattas4,6.
Abstract
BACKGROUND: Inappropriate antibiotic utilization is associated with the emergence of antimicrobial resistance (AMR) and a decline in antibiotic susceptibility in many pathogenic organisms isolated in intensive care units. Antibiotic stewardship programs (ASPs) have been recommended as a strategy to reduce and delay the impact of AMR. A crucial step in ASPs is understanding antibiotic utilization practices and quantifying the problem of inappropriate antibiotic use to support a targeted solution. We aim to characterize antibiotic utilization and determine the appropriateness of antibiotic prescription in a tertiary care pediatric intensive care unit.Entities:
Keywords: Antibiotics; Antimicrobial resistance; Antimicrobial stewardship; Children; Days of therapy; Saudi Arabia
Year: 2020 PMID: 33143749 PMCID: PMC7640689 DOI: 10.1186/s13756-020-00842-2
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Definitions and clarification of selected CDC 12-step recommendations
| CDC Step | Clarification |
|---|---|
| Step 4: Target the pathogen | Inappropriate empiric antibiotic choice based on the likely pathogen Inappropriate definitive antibiotic choice based on identified pathogen susceptibility (need for de-escalation) |
| Step 6: Practice antimicrobial control | Inappropriate prophylaxis regimen (drug or duration) Inappropriate antibiotic combination (redundant coverage) Inappropriate route of administration (requiring a shift from intravenous administration to oral) Inappropriate dose of antibiotic (based on indication, renal function, etc.) ( |
| Step 8: Treat infection, not contamination or colonization | Treating contamination or colonization and not a true, lab-confirmed confirmed infection |
| Step 9: Know when to say ‘no’ | Starting empirical vancomycin or broad-spectrum antibiotics (e.g. meropenem, piperacillin/tazobactam, or ceftazidime) unnecessarily |
| Step 10: Stop infection when cured or unlikely | Continuing antibiotics despite ruling out infection or having negative cultures or completing an appropriate duration of therapy |
Characteristics of the study cohort
| Variable | Entire cohort N = 274 | Inappropriate N = 133 | Appropriate N = 141 | P value | |||
|---|---|---|---|---|---|---|---|
| Count | Percentage | Count | Percentage | Count | Percentage | ||
| Age | |||||||
| Median months (25th–75th percentile) | 22 | (5–65) | 24 | (5–79) | 22 | (5–56) | 0.459 |
| Gender | |||||||
| Male | 132 | 50.8% | 64 | 50% | 68 | 51.9% | 0.804 |
| Female | 127 | 49.2% | 64 | 50% | 63 | 48.1% | |
| Comorbidities | |||||||
| Neurologic/neuromuscular | 96 | 35.00% | 47 | 35.30% | 49 | 34.80% | 0.510 |
| Pulmonary disease | 65 | 23.70% | 23 | 17.30% | 42 | 29.80% | 0.011 |
| Gastrointestinal | 50 | 18.20% | 24 | 18.00% | 26 | 18.40% | 0.529 |
| Metabolic diseases | 18 | 6.60% | 9 | 6.80% | 9 | 6.40% | 0.545 |
| Endocrine disease | 11 | 4.00% | 8 | 6.00% | 3 | 2.10% | 0.091 |
| Cardiac disease | 45 | 16.40% | 24 | 18.00% | 21 | 14.90% | 0.294 |
| Renal disease | 27 | 9.90% | 15 | 11.30% | 12 | 8.50% | 0.286 |
| Hematological disease | 9 | 3.30% | 3 | 2.30% | 6 | 4.30% | 0.280 |
| Preterm | 31 | 11.30% | 13 | 9.80% | 18 | 12.80% | 0.278 |
| Genetic/syndromic | 74 | 27.00% | 40 | 30.10% | 34 | 24.10% | 0.165 |
| Admission type | |||||||
| Medical | 187 | 68.2% | 75 | 56.4% | 112 | 79.4% | < 0.001 |
| Surgical | 83 | 30.3% | 57 | 42.9% | 26 | 18.4% | < 0.001 |
| Trauma | 3 | 1.1% | 1 | 0.7% | 2 | 1.4% | 0.522 |
| Burn | 1 | 0.4% | 0 | 0% | 1 | 0.8% | 0.485 |
| Number of comorbidities | |||||||
| No comorbidities | 99 | 36.10% | 50 | 37.60% | 49 | 34.80% | 0.864 |
| 1 to 2 | 130 | 47.40% | 61 | 45.90% | 69 | 48.90% | |
| 3 or more | 45 | 16.40% | 22 | 16.50% | 23 | 16.30% | |
| Type of antibiotic on initiation | |||||||
| Empiric | 187 | 68.2% | 77 | 57.9% | 110 | 78% | < 0.001 |
| Prophylactic | 61 | 22.3% | 45 | 33.8% | 16 | 11.3% | < 0.001 |
| Therapeutic/definitive | 26 | 9.5% | 11 | 8.3% | 15 | 10.6% | 0.323 |
| Indication | |||||||
| Community acquired pneumonia | 53 | 19.3% | 13 | 9.8% | 40 | 28.4% | < 0.001 |
| Sepsis, hospital acquired | 29 | 10.6% | 13 | 9.8% | 16 | 11.3% | 0.411 |
| Sepsis, community acquired | 27 | 9.9% | 13 | 10.5% | 13 | 9.2% | 0.436 |
| Bronchiolitis | 26 | 9.5% | 14 | 10.5% | 12 | 8.5% | 0.358 |
| CNS procedures e.g., EVD, VP shunt, tumor resection | 23 | 8.4% | 19 | 14.3% | 4 | 2.8% | 0.001 |
| Other | 116 | 42.3% | 60 | 45.1% | 57 | 39.7% | 0.217 |
| Documented indication in medical chart | |||||||
| Yes | 239 | 87.2% | 117 | 88% | 122 | 86.5% | 0.430 |
| No | 35 | 12.8% | 16 | 12% | 19 | 13.5% | |
| Appropriate cultures | |||||||
| Yes | 231 | 84.3% | 109 | 82% | 122 | 86.5% | 0.322 |
| No | 43 | 15.7% | 24 | 18% | 19 | 13.5% | |
| Decision at 72 h for empiric (N = 187) | |||||||
| Changed | 11 | 5.9% | 6 | 7.8% | 5 | 4.5% | 0.364 |
| Continue with planned duration | 64 | 32.2% | 25 | 32.5% | 39 | 35.5% | 0.755 |
| No action taken | 26 | 13.9% | 16 | 20.8% | 10 | 9.1% | 0.031 |
| Discontinued | 86 | 46% | 30 | 39% | 56 | 50.9% | 0.136 |
| Documented infection | |||||||
| Yes | 60 | 21.9% | 29 | 21.8% | 31 | 22% | 1 |
| No | 214 | 78.1% | 104 | 78.2% | 110 | 78% | |
| MDRO | |||||||
| Yes | 25 | 41.7% | 9 | 30% | 16 | 53.3% | 0.115 |
| No | 35 | 58.3% | 21 | 70% | 14 | 46.7% | |
Duration of antibiotics course Median days (25th–75th percentile) | 8 | 5–13 | 10 | 6–14 | 7 | 4–10 | < 0.001 |
MDRO multi-drug resistant organisms
Inappropriate antibiotics classified by CDC 12-Step
| Reason for non-adherence to the CDC 12-step campaign | Number of courses | Percentage |
|---|---|---|
| Step 6 | 48 | 36.1 |
| Step 4 | 23 | 17.3 |
| Step 10 | 21 | 15.8 |
| Step 9 | 6 | 4.5 |
| Steps 4 and 9 | 14 | 10.5 |
| Steps 4 and 10 | 11 | 8.3 |
| Steps 6 and 10 | 1 | 0.8 |
| Steps 4, 9, and 10 | 7 | 5.3 |
| Steps 4, 6 and 9 | 2 | 1.5 |
| Total | 133 courses |
Fig. 1Overall and inappropriate therapy per 1,000 patient days by antimicrobial agent